You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Keynote-D31

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in Houston (LVGN6051)

Recruiting
  • Cancer
  • LVGN6051
  • Houston, Texas
    MD Anderson Cancer Center
Nov 18, 2021

Advanced Malignancies Trial in Denmark, Hungary, Russian Federation (BI-1808, Pembrolizumab 25 Mg/mL Solution for Injection)

Recruiting
  • Advanced Malignancies
  • BI-1808
  • Pembrolizumab 25 Mg/mL Solution for Injection
  • Copenhagen, Denmark
  • +11 more
Sep 9, 2022

Melanoma Trial in Worldwide (Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B)

Active, not recruiting
  • Melanoma
  • Pembrolizumab Dose C
  • +3 more
  • Orange, New South Wales, Australia
  • +14 more
Jan 19, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

Urinary Bladder Tumors Trial in Worldwide (Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy

Recruiting
  • Urinary Bladder Neoplasms
  • Washington, District of Columbia
  • +120 more
Jan 19, 2023

Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome Trial in Minneapolis (Stem Cell Transplantation, IMD

Recruiting
  • Mucopolysaccharidosis Disorders
  • +28 more
  • Stem Cell Transplantation
  • +7 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 1, 2022

Small Cell Lung Cancer, SCLC Trial in Worldwide (Pembrolizumab, Normal saline solution, Carboplatin)

Completed
Has Results
  • Small Cell Lung Cancer (SCLC)
  • Pembrolizumab
  • +4 more
  • Miami, Florida
  • +147 more
Sep 2, 2022

Small Cell Lung Cancer Trial in Worldwide (Pembrolizumab, MK-4830, MK-5890)

Recruiting
  • Small Cell Lung Cancer
  • Pembrolizumab
  • +6 more
  • Gilbert, Arizona
  • +48 more
Jan 19, 2023

Colorectal Cancer, Lynch Syndrome, Hereditary Colorectal Cancer Trial in Moscow

Not yet recruiting
  • Colorectal Cancer
  • +3 more
    • Moscow, Russian Federation
      State Scientific Centre of Coloproctology
    Aug 8, 2022

    Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)

    Recruiting
    • Advanced Cancer
    • +24 more
    • pembrolizumab
    • Los Angeles, California
    • +21 more
    Jan 18, 2023

    Carcinoma, Squamous Cell Trial in Worldwide (Pembrolizumab 400 mg, Placebo)

    Recruiting
    • Carcinoma, Squamous Cell
    • Pembrolizumab 400 mg
    • Placebo
    • Mobile, Alabama
    • +170 more
    Jan 19, 2023

    Head and Neck Tumors Trial in Worldwide (biological, drug, radiation)

    Active, not recruiting
    • Head and Neck Neoplasms
    • Pembrolizumab
    • +4 more
    • Los Angeles, California
    • +150 more
    Dec 7, 2022

    Head Neck Cancer Trial in Worldwide (Pembrolizumab, Epacadostat, Cetuximab)

    Active, not recruiting
    Has Results
    • Head and Neck Cancer
    • Anaheim, California
    • +72 more
    Jul 28, 2022

    Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node Trial in Worldwide (Talimogene Laherparepvec,

    Active, not recruiting
    Has Results
    • Hepatocellular Carcinoma
    • +3 more
    • Scottsdale, Arizona
    • +31 more
    Dec 7, 2022

    Endometrial Tumors Trial in Worldwide (Pembrolizumab, Lenvatinib, Paclitaxel)

    Active, not recruiting
    Has Results
    • Endometrial Neoplasms
    • Phoenix, Arizona
    • +168 more
    Nov 23, 2022

    Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)

    Recruiting
    • Ovarian Cancer
    • +2 more
    • Pembrolizumab
    • +4 more
    • Phoenix, Arizona
    • +178 more
    Jan 25, 2023

    Gastric Cancer, Gastroesophageal Junction Cancer Trial in Worldwide (Pembrolizumab, Placebo, Cisplatin)

    Active, not recruiting
    • Gastric Cancer
    • Gastroesophageal Junction Cancer
    • Pembrolizumab
    • +7 more
    • Duarte, California
    • +170 more
    Aug 18, 2022

    Healthy Volunteers (Meningococcal Infection) Trial in Buenos Aires (MenACYW conjugate vaccine)

    Not yet recruiting
    • Healthy Volunteers (Meningococcal Infection)
    • MenACYW conjugate vaccine
    • Buenos Aires, Ciudad De Buenos Aires, Argentina
      Investigational Site Number :0320002
    Jul 7, 2023

    Atopic Dermatitis Trial in Germany, Poland (Lebrikizumab)

    Recruiting
    • Atopic Dermatitis
    • Lebrikizumab
    • Darmstadt, Hessen, Germany
    • +31 more
    Jun 21, 2023

    Small Cell Lung Carcinoma Trial in Worldwide (coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830)

    Active, not recruiting
    • Small Cell Lung Carcinoma
    • coformulation pembrolizumab/quavonlimab
    • +3 more
    • Gilbert, Arizona
    • +46 more
    Jan 2, 2023

    Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (biological, drug, other)

    Recruiting
    • Metastatic Castration-Resistant Prostate Cancer
    • Pembrolizumab 200 mg
    • +11 more
    • Los Angeles, California
    • +30 more
    Aug 12, 2022

    Head and Neck Squamous-cell Carcinoma

    Not yet recruiting
    • Squamous Cell Carcinoma of Head and Neck
    • +2 more
      • (no location specified)
      Nov 5, 2023

      Melanoma Trial in Worldwide (Pembrolizumab, Placebo)

      Active, not recruiting
      Has Results
      • Melanoma
      • Pembrolizumab
      • Placebo
      • Tucson, Arizona
      • +158 more
      Oct 31, 2022

      Endometrial Tumors Trial in Worldwide (pembrolizumab, carboplatin, paclitaxel)

      Recruiting
      • Endometrial Neoplasms
      • pembrolizumab
      • +4 more
      • Miami Beach, Florida
      • +106 more
      Aug 11, 2022

      Advanced NSCLC Trial in Worldwide (Pembrolizumab, Favezelimab, Lenvatinib)

      Active, not recruiting
      • Advanced Non-Small Cell Lung Cancer
      • Pembrolizumab
      • +3 more
      • Tempe, Arizona
      • +80 more
      Aug 23, 2022